Barrett's esophagus (BE) is a common condition associated with chronic gastroesophageal
reflux disease. BE is the only known precursor to esophageal adenocarcinoma, a highly …

Esophageal cancer is the sixth most common cause of cancer-related death worldwide.
Esophageal adenocarcinoma is the most common subtype of esophageal cancer in the …

Background and Aims The outcomes of endoscopic submucosal dissection (ESD) for T1b
esophageal cancer (EC) and its recurrence rates remain unclear in the West. Using a …

This clinical practice guideline from the American Society for Gastrointestinal Endoscopy
(ASGE) provides an evidence-based summary and recommendations regarding the role of …

Endoscopic eradication therapy (EET) has become a standard of care for treatment of
dysplastic Barrett's esophagus (BE) and early Barrett's neoplasia. EET mainly consists of …

Background and Aims After endoscopic resection (ER) of early esophageal
adenocarcinoma (EAC), the optimal management of patients with high-risk histologic …

METHODS: Patients who underwent EET for T1a EAC at 3 referral Barrett's esophagus
endotherapy units between 1996 and 2022 were included. Patients with submucosal …

Background: The efficacy of endoscopic therapy on the long-term survival outcomes of T1b
oesophageal cancer (EC) is unclear, this study was designed to clarify the survival …

High-risk T1 esophageal adenocarcinoma (HR-T1 EAC) is defined as T1 cancer, with one or
more of the following histological criteria: submucosal invasion, poorly or undifferentiated …

Over the past few decades, the rates of esophageal adenocarcinoma (EAC) in the USA
continue to increase, particularly in adults≥ 65 years old (Fig. 1)[1]. Barrett's esophagus …